LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Go back to LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint| Pfizer Inc. (NYSE: PFE) | Delayed: 28.81 -0.21 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.02 | 52 Week High | $37.39 | |||
| Open | $29.09 | 52 Week Low | $28.25 | |||
| Day High | $29.21 | P/E | 17.46 | |||
| Day Low | $28.44 | EPS | $1.65 | |||
| Volume | 25,193,153 | |||||
